Health Canada Approves Wegovy for MASH Treatment in 2026

New Therapeutic Indication Approved

According to Health Canada's January 2026 Health Product InfoWatch, Wegovy has received approval for the management of metabolic dysfunction-associated steatohepatitis (MASH) in adults with non-cirrhotic disease. The approval was granted through Health Canada's Notice of Compliance with conditions (NOC/c) pathway.

The NOC/c policy allows Health Canada to approve promising therapies based on preliminary evidence while requiring manufacturers to complete confirmatory studies. This regulatory mechanism is typically used when there is substantial evidence of clinical benefit and the therapy addresses serious or life-threatening conditions.

Regulatory Details

The new indication specifically covers semaglutide 2.4 mg solution for injection, which is marketed under the Wegovy brand name by Novo Nordisk. The approval document emphasizes that safety and efficacy for this specific indication are still being established through ongoing clinical trials.

Health Canada's announcement states that semaglutide is not yet approved in Canada for the treatment of MASH outside of this conditional approval framework, and there is no guarantee regarding final approval status pending completion of required studies.

Market Context

This approval comes as the Canadian GLP-1 medication landscape continues to evolve rapidly in 2026. Novo Nordisk recently launched additional semaglutide brands including Plosbrio and Poviztra, while multiple generic manufacturers are preparing applications for generic semaglutide following patent expiry in January 2026.

The conditional approval adds another therapeutic option to Canada's expanding GLP-1 medication portfolio, which also includes Ozempic and Mounjaro for various indications.

Clinical Development Requirements

Under the NOC/c framework, Novo Nordisk must complete confirmatory clinical studies to verify the clinical benefit of semaglutide for MASH treatment. The company is required to submit final study results to Health Canada within specified timelines.

• Ongoing Phase 3 clinical trials must demonstrate sustained clinical benefit
• Safety monitoring continues throughout the conditional approval period
• Regular progress reports must be submitted to Health Canada
• Final approval depends on successful completion of confirmatory studies

Healthcare System Impact

The conditional approval may impact coverage decisions across Canadian provincial drug plans and private insurance programs. Coverage policies typically require full Health Canada approval rather than conditional approval for new therapeutic indications.

Healthcare providers and patients interested in this new indication should consult current prescribing information and monitor Health Canada communications for updates on the conditional approval status. Additional information about GLP-1 medications is available through our FAQ section.